A comprehensive review of immunotherapies in prostate cancer

Critical Reviews in Oncology/Hematology

Volumn 113, Issue , 2017, Pages 292-303

  Maia, Manuel Caitano ^a   Hansen, Aaron R ^b,c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Castration resistant; Immune checkpoint inhibitor; Immunotherapy; Metastatic; Oncolytic viruses; Prostate cancer; Vaccines

Indexed keywords

ABIRATERONE; ACID PHOSPHATASE PROSTATE ISOENZYME; ANTINEOPLASTIC AGENT; CABAZITAXEL; CANCER VACCINE; CYCLOPHOSPHAMIDE; DEGARELIX; DOCETAXEL; ENZALUTAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; ITK 1; KETOCONAZOLE; LEUPRORELIN; LUTETIUM 177; METRONIDAZOLE; MONOCLONAL ANTIBODY J591; NIVOLUMAB; OLAPARIB; PEMBROLIZUMAB; PEPTIDE VACCINE; PLACEBO; POXVIRUS VACCINE; PREDNISONE; RADIUM 223; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; TASQUINIMOD; UNCLASSIFIED DRUG; UNINDEXED DRUG; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; TISSUE EXTRACT;

ANDROGEN DEPRIVATION THERAPY; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LOW DRUG DOSE; MACROPHAGE; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; OVERALL SURVIVAL; PATIENT SELECTION; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOTHERAPY; MALE; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; VACCINATION;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS; TISSUE EXTRACTS; TUMOR MICROENVIRONMENT; VACCINATION;

EID: 85018508328     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2017.02.026     Document Type: Review

References (123)

1. Abdollah, F., Schmitges, J., Sun, M., Jeldres, C., Tian, Z., Briganti, A., et al. Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis. Int. J. Urol. 19 (2012), 836–844.
2. Amato, R.J., Hawkins, R.E., Kaufman, H.L., Thompson, J.A., Tomczak, P., Szczylik, C., et al. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin. Cancer Res. 16 (2010), 5539–5547.
3. Anastasopoulou, E.A., Voutsas, I.F., Keramitsoglou, T., Gouttefangeas, C., Kalbacher, H., Thanos, A., et al. A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit. Cancer Immunol. Immunother. 64 (2015), 1123–1136.
4. Ardiani, A., Farsaci, B., Rogers, C.J., Protter, A., Guo, Z., King, T.H., et al. Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine survival in a spontaneous prostate cancer model. Clin. Cancer Res., 19, 2013.
5. Ardiani, A., Gameiro, S.R., Kwilas, A.R., Donahue, R.N., Hodge, J.W., Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway. Oncotarget 5 (2014), 9335–9348.
6. Armstrong, A.J., Haggman, M., Stadler, W.M., Gingrich, J.R., Assikis, V., Polikoff, J., et al. Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. Clin. Cancer Res. 19 (2013), 6891–6901.
7. Becker, J.T., Olson, B.M., Johnson, L.E., Davies, J.G., Dunphy, E.J., McNeel, D.G., DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J. Immunother. 33 (2010), 639–647.
8. Beer, T.M., Armstrong, A.J., Rathkopf, D.E., Loriot, Y., Sternberg, C.N., Higano, C.S., et al. PREVAIL enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med., 2014, 1–10.
9. Beer, Tomasz M., Kwon, E.D., Drake, Charles G., Fizazi, Karim, Logothetis, Christopher, Gravis, Gwenaelle, Ganju, Vinod, Polikoff, Jonathan, Saad, Fred, Humanski, Piotr, Piulats, Josep M., Gonzalez Mella, Pablo, Ng, Siobhan S., Jaeger, Dirk, Parnis, Francis X., Franke, Fabio A., Puente, Javier, Carvajal, Roman, Sengeløv, Lisa, Brent McHenry, M., Varma, Arvind, van den Eertwegh, Alfonsus J., Gerritsen, Winald, Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J. Clin. Oncol. 35:1 (2017), 40–47 Epub 2016 Oct 31.
10. Berthold, D.R., Pond, G.R., Soban, F., De Wit, R., Eisenberger, M., Tannock, I.F., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J. Clin. Oncol. 26 (2008), 242–245.
11. Bilusic, M., Gulley, J.L., Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. Cancer Immunol. Immunother. 61 (2012), 109–117.
12. Bishop, J.L., Sio, A., Angeles, A., Roberts, M.E., Azad, A.A., Chi, K.N., et al. PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. Oncotarget 6 (2015), 234–242.
13. Butts, C., Maksymiuk, A., Goss, G., Soulieres, D., Marshall, E., Cormier, Y., et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J. Cancer Res. Clin. Oncol. 137 (2011), 1337–1342.
14. Callea, M., Albiges, L., Gupta, M., Cheng, S.C., Genega, E.M., Fay, A.P., et al. Differential expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinoma. Cancer Immunol. Res. 3 (2015), 1158–1164.
15. Carbognin, L., Pilotto, S., Milella, M., Vaccaro, V., Brunelli, M., Calio, A., et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One, 10, 2015, e0130142.
16. Chen, D.S., Mellman, I., Oncology meets immunology: the cancer-immunity cycle. Immunity 39 (2013), 1–10.
17. Choueiri, T.K., Fishman, M.N., Escudier, B.J., Kim, J.J., Kluger, H.M., Stadler, W.M., et al. Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): biomarker-based results from a randomized clinical trial. J. Clin. Oncol., 32(Suppl), 2014 (5s. abstr 5012).
18. Clemente, C.G., Mihm, M.C. Jr., Bufalino, R., Zurrida, S., Collini, P., Cascinelli, N., Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77 (1996), 1303–1310.
19. De Bono, J.S., Oudard, S., Ozguroglu, M., Hansen, Sr, MacHiels, J.P., Kocak, I., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376 (2010), 1147–1154.
20. Dewan, M.Z., Galloway, A.E., Kawashima, N., Dewyngaert, J.K., Babb, J.S., Formenti, S.C., et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res. 15 (2009), 5379–5388.
21. DiPaola, R.S., Chen, Y.H., Bubley, G.J., Stein, M.N., Hahn, N.M., Carducci, M.A., et al. A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802. Eur. Urol. 68 (2015), 365–371.
22. Drake, C.G., Doody, A.D., Mihalyo, M.A., Huang, C.T., Kelleher, E., Ravi, S., et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 7 (2005), 239–249.
23. Drake, C.G., Prostate cancer as a model for tumour immunotherapy. Nat. Rev. Immunol. 10 (2010), 580–593.
24. Dunn, G.P., Old, L.J., Schreiber, R.D., The three Es of cancer immunoediting. Annu. Rev. Immunol. 22 (2004), 329–360.
25. Fernandez-Garcia, E.M., Vera-Badillo, F.E., Perez-Valderrama, B., Matos-Pita, A.S., Duran, I., Immunotherapy in prostate cancer: review of the current evidence. Clin. Transl. Oncol. 17 (2015), 339–357.
26. Flavell, R.A., Sanjabi, S., Wrzesinski, S.H., Licona-Limón, P., The polarization of immune cells in the tumour environment by TGFbeta. Nat. Rev. Immunol. 10 (2010), 554–567.
27. Formenti, S.C., Demaria, S., Combining radiotherapy and cancer immunotherapy: a paradigm shift. J. Natl. Cancer Inst. 105 (2013), 256–265.
28. Fridman, W.H., Pages, F., Sautes-Fridman, C., Galon, J., The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12 (2012), 298–306.
29. Gannon, P.O., Poisson, A.O., Delvoye, N., Lapointe, R.J., Mes-Masson, A.M., Saad, F., Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J. Immunol. Methods 348 (2009), 9–17.
30. Garnett, C.T., Schlom, J., Hodge, J.W., Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin. Cancer Res. 14 (2008), 3536–3544.
31. George, S., Motzer, R.J., Hammers, H.J., Redman, B.G., Kuzel, T.M., Tykodi, S.S., et al. Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: a subgroup analysis of a randomized clinical trial. JAMA Oncol. 2:9 (2016), 1179–1186.
32. Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366 (2012), 883–892.
33. Graff, J.N., Alumkal, J.J., Drake, C.G., Thomas, G.V., Redmond, W.L., Farhad, M., Slottke, R., Beer, T.M., First evidence of significant clinical activity of PD-1 inhibitors in metastatic, castration resistant prostate cancer (mCRPC). Ann. Oncol., 27, 2016 (Supplement 6. Abstract 719O).
34. Group, I.C.W., Sweeney, C., Nakabayashi, M., Regan, M., Xie, W., Hayes, J., et al. The development of intermediate clinical endpoints in cancer of the prostate (ICECaP). J. Natl. Cancer Inst., 107, 2015, djv261.
35. GuhaThakurta, D., Sheikh, N.A., Fan, L.Q., Kandadi, H., Meagher, T.C., Hall, S.J., et al. Humoral immune response against nontargeted tumor antigens after treatment with sipuleucel-T and its association with improved clinical outcome. Clin. Cancer Res. 21 (2015), 3619–3630.
36. Gulley, J.L., Madan, R.A., Schlom, J., Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr. Oncol. 18 (2011), 150–157.
37. Gulley, James L., Giacchino, J.L., Breitmeyer, James Bradley, Franzusoff, Alexis J., Panicali, Dennis, Schlom, Jeffrey, Kantoff, Philip W., A randomized double-blind phase 3 efficacy study of PROSTVAC-VF immunotherapy in men with asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer. J. Clin. Oncol., 33, 2015.
38. Gulley, J.L., Mulders, P., Albers, P., Banchereau, J., Bolla, M., Pantel, K., et al. Perspectives on sipuleucel-T: its role in the prostate cancer treatment paradigm. OncoImmunology, 5, 2016 (e1107698-e).
39. Gupta, N., Al Ustwani, O., Shen, L., Pili, R., Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer. Onco Targets Ther. 7 (2014), 223–234.
40. Halabi, S., Small, E.J., Kantoff, P.W., Kattan, M.W., Kaplan, E.B., Dawson, N.A., et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J. Clin. Oncol. 21 (2003), 1232–1237.
41. Hall, S.J., Klotz, L., Pantuck, A.J., George, D.J., Whitmore, J.B., Frohlich, M.W., et al. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. J. Urol. 186 (2011), 877–881.
42. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144:5 (2011), 646–674.
43. Hanna, M.G. Jr., Hoover, H.C. Jr., Pinedo, H.M., Finer, M., Active specific immunotherapy with autologous tumor cell vaccines for stage II colon cancer: logistics, efficacy, safety and immunological Pharmacodynamics. Hum. Vaccin. 2 (2006), 185–191.
44. Hansen, A., Massard, C., Ott, P.A., Haas, N., Lopez, J., Ejadi, S., Wallmark, J., Keam, B., Delord, J.-P., Aggarwal, R., Gould, M., Qiu, P., Saraf, S., Keefe, S., Piha-Paul, S.A., Pembrolizumab for patients with advanced prostate adenocarcinoma: preliminary results from the KEYNOTE-028 study. Ann. Oncol., 27, 2016 (Supplement 6. Abstract 725PD).
45. Harrington, L.E., Most Rv, R., Whitton, J.L., Ahmed, R., Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J. Virol. 76 (2002), 3329–3337.
46. Heng, T.S., Goldberg, G.L., Gray, D.H., Sutherland, J.S., Chidgey, A.P., Boyd, R.L., Effects of castration on thymocyte development in two different models of thymic involution. J. Immunol. 175 (2005), 2982–2993.
47. Higano, C.S., Corman, J.M., Smith, D.C., Centeno, A.S., Steidle, C.P., Gittleman, M., et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113 (2008), 975–984.
48. Higano, C.S., Schellhammer, P.F., Small, E.J., Burch, P.A., Nemunaitis, J., Yuh, L., et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115 (2009), 3670–3679.
49. Higano, C., Saad, F., Somer, B., Curti, B., Petrylak, D.P., Drake, C.G., et al. A phase III trial of GVAX immunotherapy for prostate cancer vs. docetaxel plus prednisone in asymptomatic castration-resistant prostate cancer (CRPC). Genitourinary Cancer Symposium, 2009.
50. Hodge, J.W., McLaughlin, J.P., Kantor, J.A., Schlom, J., Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 15 (1997), 759–768.
51. Holko, P., Kawalec, P., Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer. Expert Rev. Anticancer Ther. 14 (2014), 63–73.
52. Hoos, A., Eggermont, A.M., Janetzki, S., Hodi, F.S., Ibrahim, R., Anderson, A., et al. Improved endpoints for cancer immunotherapy trials. J. Natl. Cancer Inst. 102 (2010), 1388–1397.
53. Hoos, A., Britten, C.M., Huber, C., O'Donnell-Tormey, J., A methodological framework to enhance the clinical success of cancer immunotherapy. Nat. Biotechnol. 29 (2011), 867–870.
54. Hoos, A., Evolution of end points for cancer immunotherapy trials. Ann. Oncol. 23:Suppl. 8 (2012), viii47–52.
55. Howlader, N., Noone, A., Krapcho, M., Miller, D., Bishop, K., Altekruse, S.F., Kosary, C.L., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., Lewis, D.R., Chen, H.S., Feuer, E.J., Cronin, K.A., SEER Cancer Statistics Review, 1975–2013. 2016, National Cancer Institute, Bethesda, MD http://seer.cancer.gov/csr/1975_2013/.
56. Huber, M.L., Haynes, L., Parker, C., Iversen, P., Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J. Natl. Cancer Inst. 104 (2012), 273–279.
57. Kantoff, P.W., Higano, C.S., Shore, N.D., Berger, E.R., Small, E.J., Penson, D.F., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363 (2010), 411–422.
58. Kantoff, P.W., Schuetz, T.J., Blumenstein, B.A., Michael Glode, L., Bilhartz, D.L., Wyand, M., et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28 (2010), 1099–1105.
59. Koh, Y.T., Gray, A., Higgins, S.A., Hubby, B., Kast, W.M., Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate 69 (2009), 571–584.
60. Kubecek, O., Trojanova, P., Molnarova, V., Kopecky, J., Microsatellite instability as a predictive factor for immunotherapy in malignant melanoma. Med. Hypotheses 93 (2016), 74–76.
61. Kwon, E.D., Drake, C.G., Scher, H.I., Fizazi, K., Bossi, A., van den Eertwegh, A.J., et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 15 (2014), 700–712.
62. Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372:26 (2015), 2509–2520 (150530061707006).
63. Lee, Y., Auh, S.L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114 (2009), 589–595.
64. Longo, D.L., New therapies for castration-resistant prostate cancer. N. Engl. J. Med. 363 (2010), 479–481.
65. Lubaroff, D.M., Konety, B.R., Link, B., Gerstbrein, J., Madsen, T., Shannon, M., et al. Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin. Cancer Res. 15 (2009), 7375–7380.
66. Lubaroff, D.M., Prostate cancer vaccines in clinical trials. Expert Rev. Vaccines 11 (2012), 857–868.
67. Lugade, A.A., Moran, J.P., Gerber, S.A., Rose, R.C., Frelinger, J.G., Lord, E.M., Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 174 (2005), 7516–7523.
68. Madan, R.A., Arlen, P.M., Mohebtash, M., Hodge, J.W., Gulley, J.L., Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin. Investig. Drugs 18 (2009), 1001–1011.
69. Madan, R.A., Mohebtash, M., Arlen, P.M., Vergati, M., Rauckhorst, M., Steinberg, S.M., et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 13 (2012), 501–508.
70. Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373 (2015), 1697–1708.
71. McNeel, D.G., Dunphy, E.J., Davies, J.G., Frye, T.P., Johnson, L.E., Staab, M.J., et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J. Clin. Oncol. 27 (2009), 4047–4054.
72. Miller, A.M., Lundberg, K., Ozenci, V., Banham, A.H., Hellström, M., Egevad, L., et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J. Immunol. 177 (2006), 7398–7405.
73. Motoyoshi, Y., Kaminoda, K., Saitoh, O., Hamasaki, K., Nakao, K., Ishii, N., et al. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol. Rep. 16 (2006), 141–146.
74. Motzer, R.J., Escudier, B., McDermott, D.F., George, S., Hammers, H.J., Srinivas, S., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 180 (2015), 3–13.
75. Muller, A.J., Prendergast, G.C., Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr. Cancer Drug Targets 7 (2007), 31–40.
76. Naito, Y., Saito, K., Shiiba, K., Ohuchi, A., Saigenji, K., Nagura, H., et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58 (1998), 3491–3494.
77. Noguchi, M., Kakuma, T., Uemura, H., Nasu, Y., Kumon, H., Hirao, Y., et al. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol. Immunother. 59 (2010), 1001–1009.
78. Noguchi, M., Koga, N., Moriya, F., Itoh, K., Immunotherapy in prostate cancer: challenges and opportunities. Immunotherapy 8 (2016), 69–77.
79. Noguchi, M., Moriya, F., Koga, N., Matsueda, S., Sasada, T., Yamada, A., et al. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer. Cancer Immunol. Immunother. 65 (2016), 151–160.
80. Pages, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353 (2005), 2654–2666.
81. Parker, C., Nilsson, S., Heinrich, D., Helle, S.I., O'Sullivan, J.M., Fossa, S.D., et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369 (2013), 213–223.
82. Pasero, C., Gravis, G., Guerin, M., Granjeaud, S., Thomassin-Piana, J., Rocchi, P., et al. Inherent and tumor-driven immune tolerance in the prostate microenvironment impairs natural killer cell antitumor activity. Cancer Res. 76 (2016), 2153–2165.
83. Perez, S.A., Kallinteris, N.L., Bisias, S., Tzonis, P.K., Georgakopoulou, K., Varla-Leftherioti, M., et al. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer. Clin. Cancer Res. 16 (2010), 3495–3506.
84. Pili, R., Haggman, M., Stadler, W.M., Gingrich, J.R., Assikis, V.J., Bjork, A., et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J. Clin. Oncol. 29 (2011), 4022–4028.
85. Predina, J., Eruslanov, E., Judy, B., Kapoor, V., Cheng, G., Wang, L.C., et al. Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), E415–E424.
86. Reis, S.T.D., Pontes-Júnior, J., Antunes, A.A., Sousa-Canavez, JMd, Abe, D.K., Cruz, JASd, et al. Tgf-β1 expression as a biomarker of poor prognosis in prostate cancer. Clinics 66 (2011), 1143–1147.
87. Ren, R., Koti, M., Hamilton, T., Graham, C.H., Nayak, J.G., Singh, J., et al. A primer on tumour immunology and prostate cancer immunotherapy. J. Can. Urol. Assoc. 10 (2016), 60–65.
88. Rice, J., Ottensmeier, C.H., Stevenson, F.K., DNA vaccines: precision tools for activating effective immunity against cancer. Nat. Rev. Cancer 8 (2008), 108–120.
89. Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
90. Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372:26 (2015), 2521–2532 (150419053123009).
91. Rosenberg, J.E., Hoffman-Censits, J., Powles, T., van der Heijden, M.S., Balar, A.V., Necchi, A., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387 (2016), 1909–1920.
92. Ryan, C.J., Smith, M.R., Fizazi, K., Saad, F., Mulders, P.F., Sternberg, C.N., et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 16 (2015), 152–160.
93. Sato, E., Olson, S.H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 18538–18543.
94. Schaue, D., Ratikan, J.A., Iwamoto, K.S., McBride, W.H., Maximizing tumor immunity with fractionated radiation. Int. J. Radiat. Oncol. Biol. Phys. 83 (2012), 1306–1310.
95. Schellhammer, P.F., Chodak, G., Whitmore, J.B., Sims, R., Frohlich, M.W., Kantoff, P.W., Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology 81 (2013), 1297–1302.
96. Scher, H.I., Solo, K., Valant, J., Todd, M.B., Mehra, M., Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model. PLoS One, 10, 2015, e0139440.
97. Schlom, J., Therapeutic cancer vaccines: current status and moving forward. J. Natl. Cancer Inst. 104 (2012), 599–613.
98. Schreiber, R.D., Old, L.J., Smyth, M.J., Cancer immunoediting integrating immunity's roles in cancer suppression and promotion. Science 331 (2011), 1565–1570.
99. Sfanos, K.S., Bruno, T.C., Maris, C.H., Xu, L., Thoburn, C.J., Demarzo, A.M., et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals T H17 and Treg skewing. Clin. Cancer Res. 14 (2008), 3254–3261.
100. Shafer-Weaver, Ka, Anderson, M.J., Stagliano, K., Malyguine, A., Greenberg, N.M., Hurwitz, Aa., Cutting Edge Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells. J. Immunol. 183 (2009), 4848–4852.
101. Sheikh, N.A., Small, E., Quinn, D.I., Higano, C.S., Lin, D.W., Wesley, J.D., Hay- nes, H., Stewart, F.P., Poehlein, C.H., Trager, J.B., Sipuleucel-T product characterization across different disease states of prostate cancer. J. Clin. Oncol., 30, 2012.
102. Shen, L., Sundstedt, A., Ciesielski, M., Miles, K.M., Celander, M., Adelaiye, R., et al. Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunol Res. 3 (2015), 136–148.
103. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J. Clin. 66 (2016), 7–30.
104. Simons, J.W., Sacks, N., Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol. Oncol. 24 (2006), 419–424.
105. Small, E.J., Schellhammer, P.F., Higano, C.S., Redfern, C.H., Nemunaitis, J.J., Valone, F.H., et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24 (2006), 3089–3094.
106. Small, E.J., Sacks, N., Nemunaitis, J., Urba, W.J., Dula, E., Centeno, A.S., et al. Granulocyte macrophage colony-stimulating factor–secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res. 13 (2007), 3883–3891.
107. Small, E., Demkow, T., Gerritsen, W., et al. A Phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel vs docetaxel plus prednisone in symptomatic, castration resistant prostate cancer (CRPC). Genitourinary Cancer Symposium, 2009.
108. Small, E.J., Lance, R.S., Gardner, T.A., Karsh, L.I., Fong, L., McCoy, C., et al. A randomized phase II trial of sipuleucel-T with concurrent versus sequential abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 21 (2015), 3862–3869.
109. Smyth, M.J., Dunn, G.P., Schreiber, R.D., Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 90 (2006), 1–50.
110. Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J.M., Desrichard, A., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371 (2014), 2189–2199.
111. Sternberg, C., Armstrong, A., Pili, R., Ng, S., Huddart, R., Agarwal, N., et al. Randomized, double-blind, placebo-controlled phase III study of tasquinimod in men with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 34:22 (2016), 2636–2643.
112. Taube, J.M., Anders, R.A., Young, G.D., Xu, H., Sharma, R., McMiller, T.L., et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med., 4, 2012, 127ra37.
113. Taube, J.M., Klein, A., Brahmer, J.R., Xu, H., Pan, X., Kim, J.H., et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20 (2014), 5064–5074.
114. Thoma, C., Prostate cancer: towards effective combination of ADT and immunotherapy. Nat. Rev. Urol., 13(6), 2016, 300.
115. Thompson, R.H., Gillett, M.D., Cheville, J.C., Lohse, C.M., Dong, H., Webster, W.S., et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 17174–17179.
116. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366 (2012), 2443–2454.
117. van Houdt, I.S., Sluijter, B.J., Moesbergen, L.M., Vos, W.M., de Gruijl, T.D., Molenkamp, B.G., et al. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. Int. J. Cancer 123 (2008), 609–615.
118. van den Eertwegh, A.J., Versluis, J., van den Berg, H.P., Santegoets, S.J., van Moorselaar, R.J., van der Sluis, T.M., et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 13 (2012), 509–517.
119. Wang, X., Yu, J., Sreekumar, A., Varambally, S., Shen, R., Giacherio, D., et al. Autoantibody signatures in prostate cancer. N. Engl. J. Med. 353 (2005), 1224–1235.
120. Weber, J.S., D'Angelo, S.P., Minor, D., Hodi, F.S., Gutzmer, R., Neyns, B., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 37 (2015), 5–84.
121. Wolchok, J.D., Hoos, A., O'Day, S., Weber, J.S., Hamid, O., Lebbe, C., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15 (2009), 7412–7420.
122. Yuan, J., Page, D.B., Ku, G.Y., Li, Y., Mu, Z., Ariyan, C., et al. Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. Cancer Immun., 10, 2010, 1.
123. Zhang, Q., Liu, S., Zhang, Q., Xiong, Z., Wang, A.R., Myers, L., et al. Interleukin-17 promotes development of castration-resistant prostate cancer potentially through creating an immunotolerant and pro-angiogenic tumor microenvironment. Prostate 74 (2014), 869–879.